Advanced Oncotherapy (AVO) – Major Shareholder increases stake
NOTIFICATION OF MAJOR INTEREST IN SHARES download movie War for the Planet of the Apes 2017 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Advanced Oncotherapy plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal […]
Brand CEO Alan Green talks Advanced Oncotherapy (AVO), Burford Capital (BUR) and Independent Oil & Gas (IOG) on Vox Markets podcast
Brand CEO Alan Green talks Advanced Oncotherapy (AVO), Burford Capital (BUR) and Independent Oil & Gas (IOG) with Justin Waite on the Vox Markets podcast. The interview is exactly 40 minutes in.
Advanced Oncotherapy (AVO) – Updated major shareholder list to include Bracknor Investment Group
Advanced Oncotherapy (AVO) – Major Shareholders Shares in issue: 72,467,783 Major Shareholders Information Shareholder Number of Shares % of Total In Issue Brahma AG 10,850,491 15.0% Mr Michael Stephen Bradfield 7,080,740 9.8% MK Trust Co., LTD 4,850,000 6.7% Michael Sinclair & Family 4,628,229 6.4% Banca Profilo SPA 3,750,000 5.2% Hargreaves Lansdown Asset Mgt 3,592,410 5.0% […]
Advanced Oncotherapy (AVO) – Posting of Circular, Notice of General Meeting and Update on Financing Options
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that a circular containing a Notice of General Meeting has been posted to Shareholders. The purpose of the Circular is to explain the background to the proposed Equity Financing Facility with Bracknor announced on 22 February 2017 and why the […]
Advanced Oncotherapy (AVO) – Investor presentation and Update
Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, will be hosting investor and analyst presentations in London later today and in Zürich, Switzerland, the following day, Tuesday 7 March 2017. The presentations will outline some of the key aspects of Advanced Oncotherapy’s technology, the clinical benefits of proton therapy, the rationale […]
Advanced Oncotherapy (AVO) – Conversion of convertible loan notes
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group has advised the Company that they will convert a portion of the first tranche of the Convertible Loan Notes issued to them on 22 February 2017 into new ordinary shares of 25p each in the share […]
Advanced Oncotherapy (AVO) – Update on financing and Harley Street building work update
Advanced Oncotherapy (AVO), the developer of next generation proton therapy systems for cancer treatment, announces that further to the financing agreement with Bracknor announced on 22 February 2017, the first tranche has been drawn down by the Company and the initial funds of £1.3 million received (less 5%, in accordance with terms for receipt of […]
Brand CEO Alan Green discusses Feedback (FDBK), Advanced Oncotherapy (AVO) & Defenx (DFX) on VOX Markets podcast
Brand CEO Alan Green discusses Feedback (FDBK), Advanced Oncotherapy (AVO) & Defenx (DFX) with Justin Waite on the VOX Markets podcast. The interview is 35 minutes, 29 seconds in.
Advanced Oncotherapy (AVO) – Financing agreement
Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces it has secured a flexible and staged £26 million financing agreement with Bracknor Investment Group, a Dubai-based investment firm. The Agreement gives the Company the ability to issue a minimum of £13 million in convertible loan notes (Minimum […]
Advanced Oncotherapy (AVO) – Investor Presentations
Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that it will be hosting investor and analyst presentations in London on Monday 6 March 2017 and in Zürich, Switzerland the following day, Tuesday 7 March 2017. The presentations will outline some of the key aspects of Advanced Oncotherapy’s […]